KLAS
4.6.2024 11:01:28 CEST | Business Wire | Press release
Klas, a global leader in rugged edge technology solutions, is proud to unveil its most advanced vehicle data logging solution yet - the TRX D16. This cutting-edge device combines high-performance computing (HPC) and storage into a single platform, revolutionizing ADAS/AD development and data logging for both lab and in-vehicle use.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240604506618/en/
TRX D16 from Klas - HPC ADAS/AD Development Server & Cloud Scale Data Logging (Photo: Business Wire)
The TRX D16 introduces transformational advancements to in-vehicle computing and logging and unleashes technology confined to the cloud or extremely large loggers up to this point. Now, high-end computing and logging can be fitted to any vehicle platform, allowing engineers to continue pushing the limits of ADAS/AD.
With TRX D16, automotive engineers gain a high-performance and customizable platform to accommodate the evolving vehicle sensor stack and support compute-intensive software development of AI/ML training, inference, and simulation. Furthermore, the platform delivers 200Gbps of sustained logging speeds and 480TB of data storage to capture data from high-speed ethernet-based cameras, with support for denser radar and lidar point cloud captures.
Designed rugged, the TRX D16 is equally at home in the lab and the vehicle. Engineers can transfer the entire development environment workbench to the vehicle for continued development and integration of new functionality with real-world drive test scenarios.
“As a single platform, the multi-purpose TRX D16 minimizes the number of disparate systems in the vehicle and reduces the effort of moving from the lab to the vehicle,” said Frank Murray, CTO of Klas. “By reducing the time spent preparing the vehicle, engineers can focus on productive tasks of real-world validation, which includes high-performance computing for AI testing. At a program level, the result is the improved time to market for new ADAS/AD functionality.”
TRX D16 key features
The TRX D16 is designed rugged to the highest specifications of MIL-STD-461 and 810G/H to withstand the extremes of temperature, vibration and shock.
- High performance computing: AMD EPYC™ 7713P (64 core) processor and up to 768GB of RAM, designed for embedded and harsh environments in vehicles.
- Open GPU options: Numerous GPU PCIe card options are supported, allowing for more flexible and cost-effective AI/ML development environments.
- Hot-swappable storage: 480 TB storage (16x SSDs) split over two removable cassettes allows test vehicles to return to the road in minutes with minimal IT effort.
- High disk write speeds: SAS4 SED drives, plus integrated RAID for secure data capture from an increased number of high-bandwidth sensors.
- High speed connectivity: 2x 100GbE interfaces to transfer valuable data to engineering HIL/SIL workbenches.
- Flexible expansion: 2x PCIe (Gen 4) interfaces for custom I/O - automotive Ethernet, FPGA based SmartNICs, GMSL/FPD-Link/GVIF based cameras, or storage.
To learn more about the TRX D16 HPC server and vehicle data logger or Klas, visit -
https://www.klasgroup.com/markets/automotive/l4-l5-data-logging/
About Klas
Klas is an engineering and design company with over 30 years of experience developing innovative rugged communications solutions for the network edge. The company specializes in integrating enterprise networking capabilities from global IT leaders with purpose-built hardware and software platforms designed to meet market demands and the most stringent environmental requirements. Klas collaborates with strategic partners, including Cisco, Dell, and Microsoft, to support edge deployments in Government, Transportation, and Automotive industries. For more information, visit www.klasgroup.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240604506618/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet TechSparq25.10.2026 06:09:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med TechSparq, en amerikansk virksomhed, der kombinerer strategi, commerce engineering og ai med praktisk implementering. TechSparq er et digitalt konsulenthus, der tilbyder strategi- og rådgivningstjenester, commerce engineering samt tjenester inden for ai og agentbaseret handel til virksomheder inden for detailhandel og forbrugsgoder, luksus og mode samt e-handel og direkte salg til forbrugere. Virksomheden har hovedkontor i Oregon og kombinerer strategisk planlægning med praktisk implementering for at hjælpe kunderne med at udvikle deres digitale initiativer, kundeoplevelse og driftsmodeller. "Vi etablerede vores virksomhed for at bygge bro mellem dem, der udvikler strategien, og dem, der har ansvaret for at føre den ud i livet," udtalte Dedrick Boyd, stifter af og administrerende direktør for TechSparq. "Vores samarbejde med Andersen Consulting giver os mulighed
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press release
Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancerBrain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient datasetFirst clinical data of CEA-targeting ADC demonstrates encouraging and sustained responses in CEAhigh NSCLC BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to dise
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom